We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Synovial Fluid NGAL Accurately Diagnoses Prosthetic Joint Infection

By LabMedica International staff writers
Posted on 04 Oct 2022
Print article
Image: Neutrophil gelatinase-associated lipocalin (NGAL) Duo Set ELISA (Photo courtesy of R&D Systems)
Image: Neutrophil gelatinase-associated lipocalin (NGAL) Duo Set ELISA (Photo courtesy of R&D Systems)

Prosthetic joint infection (PJI) is a serious complication that is difficult to diagnose after joint arthroplasty and seriously affects the physical and mental health of patients. Current studies suggest that PJI is a relatively limited infectious disease, and the synovial fluid (SF) biomarkers more directly reflect the nature and extent of inflammation.

The previous use of antimicrobial therapies will significantly decrease the sensitivities of either serum or the synovial fluid (SF) biomarkers. Inaccurate diagnosis may lead to incorrect treatment options and poor prognosis. Neutrophil gelatinase-associated lipocalin (NGAL) has been used for the early identification of bacterial and viral infections in blood and cerebrospinal fluid.

Orthopaedic Surgeons at the Fujian Medical University (Fuzhou, China) included in a prospective study in a single osteoarticular infection referral center, in which consecutive patients who needed revision surgery after hip and knee arthroplasty due to PJI or aseptic prosthesis loosening from January 2017 to September 2018. A total of 78 patients who underwent hip or knee revision surgery were included in the study.

The scientists collected 0.5 mL of the SF for the white blood cell count (SF-WBC) and neutrophil classification. A total of 1 mL of the SF was frozen at -80 °C for NGAL determination. The remaining SF was used for microbiological culture. SF was injected into Bactec Plus/F aerobic or Bactec Peds Plus/F blood culture bottles and anaerobic blood culture bottles (Becton-Dickinson, Heidelberg Germany). The plates and bottles were incubated for 14 days in a Bactec 9050 automatic incubator.

The periprosthetic tissue was cut into pieces, added to the broth for grinding, and then cultured for aerobic and anaerobic bacteria on a blood plate for 14 days. The Vitek II system (bioMérieux, Durham, NC, USA) was used for microbial identification and antibiotic susceptibility testing. The SF samples were centrifuged and diluted appropriately before assaying. The team determined NGAL levels using the NGAL Duo Set ELISA Kits (R&D Systems, Minneapolis, MN, USA). The level of NGAL in the SF was measured in duplicate.

The investigators reported that a total of 50 of 78 included patients were diagnosed with PJI. A total of 40 cases were positively cultured. The most common pathogen was Staphylococcus aureus in 10 (25%) patients, followed by coagulase-negative staphylococci in seven patients, and gram-negative bacilli in seven patients (17.5%), and other pathogens in 16 patients. The median SF-NGAL level was 3,633 ng/mL (interquartile range [IQR], 1,332-10,737) in the PJI group and 26.8 ng/mL (IQR, 12.4-52.5) in the aseptic failure group. When the SF-NGAL threshold was 263 ng/mL, the area under the curve was 0.98, the sensitivity was 92.9%, and the specificity was 98%. The median level was 5,779 ng/mL (IQR, 1425-13,072) in the antibiotic group and 2,590 ng/mL (IQR, 932-8,970) in the non-antibiotic group.

The authors concluded that NGAL in the SF has both high sensitivity and specificity for the PJI diagnostics. The previous use of antibiotics does not affect the level of the SF-NGAL. The SF-NGAL can be used as a potential laboratory indicator for diagnosing PJI. The study was published on October 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
Fujian Medical University 
Becton-Dickinson 
bioMérieux 
R&D Systems 

New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Control Material
Blood Culture Identification Control Panel
New
Anti-Rubella IgG (Rubella IgG) Test
Rubella IgG AccuBind ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The MCED test can screen for up to 42 solid tumors and five hematological tumors (Photo courtesy of 123RF)

Non-Invasive Test Detects Up To 42 Solid Tumors and Five Blood Cancers in Blood and Urine Samples

Cancer is now responsible for nearly 1 in 6 deaths worldwide. Each year, over 14 million people are diagnosed with cancer, and this number is expected to surpass 21 million by 2030. A major issue is that... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: The PAXgene Urine Liquid Biopsy Set is the first standardized preanalytical workflow that stabilizes cell-free DNA in urine for subsequent analysis (Photo courtesy of PreAnalytiX)

Liquid Biopsy Solution Enables Non-Invasive Sample Collection and Direct Cell-Free DNA Stabilization from Urine

Urine cell-free DNA (cfDNA) presents significant potential for research and future clinical applications. It facilitates the measurement and analysis of cfDNA fragments, detection of genetic alterations,... Read more

Industry

view channel
Image: International expert meeting for trends and innovations in laboratory medicine - the MEDICA LABMED FORUM at MEDICA (Photo courtesy of Constanze Tillmann/Messe Düsseldorf)

MEDICA LABMED FORUM 2024: International Experts Meet to Discuss Trending Topics in Laboratory Medicine

At MEDICA (Düsseldorf, Germany), the world’s premier trade fair for the healthcare industry and medical technology sector, this year’s event (November 11–14) will focus on the most exciting medical advancements.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.